Gufic Biosciences Limited has informed the Exchange about Update on further investment in Selvax Pty Ltd. ( Selvax )
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gufic Biosciences has made an additional investment of USD 50,000 in Selvax Pty Ltd., an Australian biotechnology company. The investment involved subscribing to 378,350 ordinary shares at AUD 20 cents per share on April 28, 2026. Following this investment, Gufic now holds 1,685,350 shares in Selvax. Selvax is developing a novel immunology-based treatment for large solid tumours targeting both human and veterinary oncology. The company reported total income of AUD 356,972 for the year ended June 2025. This investment represents Gufic's strategic move to diversify into the healthcare and biotechnology sector.
This small strategic investment signals Gufic Biosciences' intent to diversify beyond its core business into biotechnology. While the investment amount is modest (USD 50,000), it provides exposure to potential proprietary oncology technology. The direct impact on Gufic's stock price is likely minimal in the near term given the small investment size.